KPV
A potent anti-inflammatory tripeptide derived from alpha-melanocyte-stimulating hormone that reduces intestinal and systemic inflammation.
Also known as: Lysine-Proline-Valine, Alpha-MSH C-terminal tripeptide
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
Inhibits NF-κB and MAPK pathways via PepT1 transporter-mediated intracellular uptake. Suppresses pro-inflammatory cytokine secretion (TNF-α, IL-6) in intestinal and respiratory epithelial cells.
Key Benefits
- ✓Reduces gut inflammation and SASP markers
- ✓Suppresses pro-inflammatory cytokines
- ✓Supports intestinal barrier integrity
- ✓Anti-inflammatory response activation
- ✓Immune modulation without immunosuppression
Dosing Protocols
Beginner / Intermediate
Dose
250-500 mcg
Frequency
Once or twice daily oral on empty stomach
Cycle Length
4 weeks
Notes
Take 30-60 minutes before food for optimal absorption
Advanced
Dose
500 mcg
Frequency
Twice daily subcutaneous
Cycle Length
6-8 weeks
Notes
Subcutaneous delivery maximizes systemic anti-inflammatory effects
Side Effects & Safety
Common Side Effects
- Mild nausea or GI disturbance
- Transient flu-like symptoms
- Histamine sensitivity in MCAS individuals
- Generally well-tolerated and transient
Contraindications
- Mast cell activation syndrome (MCAS)
- Severe histamine intolerance
- Pregnancy and lactation
- Active malignancy
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Calm systemic inflammation at the source: KPV blocks NF-κB to reduce pro-inflammatory cytokines.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.